Form 8-K AERIE PHARMACEUTICALS For: Aug 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St rises as oil falls heading into US midterm elections, more earnings
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 6% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
- Marvell agrees to acquire Lumentum in all-stock deal valued at $115B
- Cerebras shares fall as UBS cuts price target
- Cipher Digital posts Q3 revenue of $27M, logs first HPC lease income
- Alphabet shares rise as analysts back stock after selloff
- Oracle files to offer $10B in common stock alongside senior notes
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Aerie Pharma (AERI) PT Lowered to $24 at Needham & Company
August 5, 2021 6:37 AM EDTNeedham & Company analyst Serge Belanger lowered the price target on Aerie Pharma (NASDAQ: AERI) to $24.00 (from $26.00) while maintaining a Buy rating.
The analyst commented, "AERI reported solid 2Q21 earnings with glaucoma sales of $27.2MM (+18%Q/Q and +51%Y/Y) that outpaced Street... More



